Fig. 3

Suppressive effects of AC-93253 iodide on tumor cell growth. a AC-93253 iodide reduced proliferation in PC9, PC9/gef, A549, and H1975 cells as determined by PrestoBlue cell viability assays at the indicated time points. b AC-93253 iodide inhibited clonogenicity, as determined by colony formation assay. Upper panel: anchorage-dependent cell growth, colonies with diameters ≥ 0.3 mm were counted; lower panel: anchorage-independent cell growth, colony diameter ≥ 0.5 mm. Each experiment was performed independently and in triplicate; 0 nM: 0.1% DMSO. c Tumourigenesis assay. The indicated number of live PC9/gef cells was subcutaneously injected into mice divided into vehicle-treated (n = 8) and drug-treated groups (n = 6). Tumor volumes were measured every 3–4 days. d AC-93253 iodide decreased tumor weights, which were presented as the mean ± standard deviation. e pSrc and Src expression levels and distributions in murine tumor tissues were determined by immunohistochemical staining and observed using a light microscope (×400 magnification). Vehicle represents 0.1% DMSO, and AC-93253 represents 0.25 mg/kg of the compound. The scale bars represent 20 μm. *P < 0.05 compared with the vehicle control (0 nM, 0.1% DMSO)